SynthesisFrontiers in immunology2025
The impact of comorbid COPD on survival outcomes in lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Can tissue immune states shape the risk of hyperprogressive disease?Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer (LC) remains the leading cause of cancer-related death worldwide. While immune checkpoint inhibitors (ICIs) have demonstrated survival benefits in advanced-stage disease, treatment responses exhibit significant heterogeneity across patients. The potential role of comorbid chronic obstructive pulmonary disease (COPD) in modulating survival outcomes from ICIs therapy remains controversial, with conflicting evidence regarding its synergistic or antagonistic effects. This meta-analysis systematically evaluates the impact of COPD on survival outcomes in lung cancer patients receiving ICIs, aiming to clarify its prognostic value and guide precision immunotherapy strategies. Methods: We systematically searched PubMed, Cochrane Library, CNKI, and EMBASE for studies published up to March 31, 2025, to evaluate the synergistic survival impact of comorbid COPD in lung cancer patients receiving ICIs. Primary outcomes included overall survival (OS) and progression-free survival (PFS). Results: This study pooled data from 10 studies (N = 6,909) to assess the impact of comorbid COPD on survival outcomes among LC patients receiving ICIs. The meta-analysis revealed that LC patients with comorbid COPD showed significant improvements in OS (HR = 0.90, 95% CI: 0.85-0.96, p < 0.001) and PFS (HR = 0.54, 95% CI: 0.44-0.67, p < 0.001) compared to those without COPD. Notably, while bias analysis for PFS indicated potential bias, inter-subgroup heterogeneity was negligible (I² = 0%). Conclusions: This study demonstrated that the presence of comorbid COPD was associated with significantly improved overall survival in lung cancer patients receiving ICIs. Although a significant progression-free survival benefit was also observed, this result may be influenced by potential publication bias. Further prospective studies that incorporate comprehensive biomarker analyses are warranted to validate the observed COPD-ICIs interaction and to develop optimized, personalized treatment strategies for this patient population. Systematic Review Registration: www.inplasy.com, identifier INPLASY202580086.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.